In HER2-positive breast cancer patients, the first targeted drug to be approved is trastuzumab [53]; however, a large number of patients have shown primary or acquired resistance, which is significantly related to the hypermethylation of the tumor suppressor gene transforming growth factor beta induced (GFBI) promoter [54]. Here, ERBB2 is linked to breast carcinoma.